A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. We’re inching closer to having the first-ever needle-free weight loss drug. That’s thanks to Novo Nordisk, which expects a U.S. approval for its daily pill for chronic…
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters New trial data suggests Novo Nordisk‘s weight loss drug Wegovy edges out rival treatments on heart condition risk reduction, in good news for the Danish pharma giant as it…
Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. Mike Blake | Reuters Eli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the way for the company to…
Eternalcreative | Istock | Getty Images Miracle drugs, obesity treatments and skinny jabs. Call them what you will, few drugs have had a more transformative effect on Wall Street and waistlines over recent decades than GLP-1s. Familiarly known under the brand names Wegovy and Zepbound, Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medication used to…
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial,…
This report is from this week’s CNBC’s UK Exchange newsletter. Each Wednesday, Ian King brings you expert insights on the most important business stories from the U.K. and other key developments you won’t want to miss. Like what you see? You can subscribe here. The dispatch Episodes in which the mighty KKR receives a bloody nose…
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks aren’t moving much Monday as Wall Street waits on retail earnings and a speech from Fed Chair Jay Powell later in the week. Monday’s…
The stock market ended the week higher as Wall Street speculated on how a spate of economic releases would impact the Federal Reserve’s next interest rate decision. The S & P 500 and Nasdaq both gained nearly 1% over the past five sessions. Both benchmark gauges hit several record closes this week, with the S…
CNBC’s Jim Cramer on Thursday said that although the market may be frothy, investors shouldn’t quit because there are enough positive stock stories to overwhelm the froth with rationality. Cramer used the dotcom bubble burst as an example. During that time in the late 1990s, he said froth involved the market’s continuous roar based on,…
My top 10 things to watch Monday, Aug. 11 1. Melius Research’s Ben Reitzes downgraded Adobe to sell from hold, arguing that an AI-driven multiple contraction phase is in the early innings for software-as-a-service (SaaS) companies. That includes the likes of Atlassian and Club stock Salesforce . It can still get worse for these names,…
